MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:MNKD
- CUSIP: 56400P20
- Web: www.mannkindcorp.com
- Market Cap: $156.56 million
- Outstanding Shares: 101,006,000
- 50 Day Moving Avg: $1.32
- 200 Day Moving Avg: $1.08
- 52 Week Range: $0.67 - $6.50
Sales & Book Value:
- Trailing P/E Ratio: 1.07
- Foreward P/E Ratio: -1.94
- P/E Growth: -0.07
- Annual Revenue: $177.77 million
- Price / Sales: 0.88
- Book Value: ($2.08) per share
- Price / Book: -0.75
- EBIDTA: $65.91 million
- Return on Equity: -23.44%
- Return on Assets: 54.12%
- Debt-to-Equity Ratio: -0.39%
- Current Ratio: 0.60%
- Quick Ratio: 0.56%
- Average Volume: 3.64 million shs.
- Beta: 3.42
- Short Ratio: 4.06
Frequently Asked Questions for MannKind Corporation (NASDAQ:MNKD)
What is MannKind Corporation's stock symbol?
MannKind Corporation trades on the NASDAQ under the ticker symbol "MNKD."
How were MannKind Corporation's earnings last quarter?
MannKind Corporation (NASDAQ:MNKD) released its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.08. The firm earned $3 million during the quarter, compared to analysts' expectations of $3.50 million. The company's revenue for the quarter was up 2900.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.06) EPS. View MannKind Corporation's Earnings History.
Where is MannKind Corporation's stock going? Where will MannKind Corporation's stock price be in 2017?
2 brokers have issued 12-month price targets for MannKind Corporation's stock. Their forecasts range from $0.83 to $1.00. On average, they anticipate MannKind Corporation's share price to reach $0.92 in the next year. View Analyst Ratings for MannKind Corporation.
Are investors shorting MannKind Corporation?
MannKind Corporation saw a increase in short interest in May. As of May 31st, there was short interest totalling 25,804,478 shares, an increase of 7.9% from the May 15th total of 23,909,169 shares. Based on an average daily trading volume, of 5,163,803 shares, the days-to-cover ratio is currently 5.0 days. Approximately 46.8% of the company's shares are sold short.
Who are some of MannKind Corporation's key competitors?
Some companies that are related to MannKind Corporation include Minerva Neurosciences (NERV), GlycoMimetics (GLYC), Akebia Therapeutics (AKBA), Merus N.V. (MRUS), Ovid Therapeutc (OVID), Chimerix (CMRX), Circassia Pharmaceuticals PLC (CIR), AVEO Pharmaceuticals (AVEO), TOCAGEN INC (TOCA), Ardelyx (ARDX), Clearside Biomedical (CLSD), Immune Design Corp. (IMDZ), Catalyst Pharmaceuticals (CPRX), Cempra (CEMP), DURECT Corporation (DRRX), Zymeworks (ZYME), Stemline Therapeutics (STML) and Kindred Biosciences (KIN).
Who are MannKind Corporation's key executives?
MannKind Corporation's management team includes the folowing people:
- Kent Kresa, Chairman of the Board
- Michael E. Castagna Pharm.D., Chief Executive Officer, Director
- Rosabel R. Alinaya, Acting Chief Financial Officer, Senior Vice President, Chief Accounting Officer
- Linda Adreveno, Senior Vice President - Human Resources
- Joseph Kocinsky, Chief Technology Officer, Corporate Vice President
- David B. Thomson Ph.D., J.D., Corporate Vice President, General Counsel, Corporate Secretary
- Raymond W. Urbanski M.D., Ph.D., Corporate Vice President, Chief Medical Officer
- Stuart A. Tross Ph.D., Chief People Officer
- James Samuel Shannon M.D., Director
- Ronald J. Consiglio, Independent Director
Who owns MannKind Corporation stock?
MannKind Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include
FLYNN JAMES E
(5.17%), Vanguard Group Inc. (3.10%), Morgan Stanley (0.57%), Harel Insurance Investments & Financial Services Ltd. (0.51%), Geode Capital Management LLC (0.50%) and Bank of New York Mellon Corp (0.29%). Company insiders that own MannKind Corporation stock include Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya. View Institutional Ownership Trends for MannKind Corporation.
Who sold MannKind Corporation stock? Who is selling MannKind Corporation stock?
MannKind Corporation's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Harel Insurance Investments & Financial Services Ltd., Geode Capital Management LLC, Morgan Stanley, Bank of New York Mellon Corp, TIAA CREF Investment Management LLC, Wells Fargo & Company MN and Teachers Advisors LLC. View Insider Buying and Selling for MannKind Corporation.
Who bought MannKind Corporation stock? Who is buying MannKind Corporation stock?
MannKind Corporation's stock was acquired by a variety of institutional investors in the last quarter, including KCG Holdings Inc.. Company insiders that have bought MannKind Corporation stock in the last two years include Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya. View Insider Buying and Selling for MannKind Corporation.
How do I buy MannKind Corporation stock?
Shares of MannKind Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MannKind Corporation's stock price today?
MarketBeat Community Rating for MannKind Corporation (NASDAQ MNKD)MarketBeat's community ratings are surveys of what our community members think about MannKind Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of MannKind Corporation stock can currently be purchased for approximately $1.55.
Consensus Ratings for MannKind Corporation (NASDAQ:MNKD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings|
|Consensus Rating:||Sell (Score: 1.00)|
|Consensus Price Target: ||$0.92 (40.97% downside)|
Analysts' Ratings History for MannKind Corporation (NASDAQ:MNKD)
(Data available from 6/28/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/22/2017||J P Morgan Chase & Co||Reiterated Rating||Underweight||High|
|5/11/2017||Piper Jaffray Companies||Set Price Target||Sell||$1.00||Medium|
|5/8/2017||S&P Equity Research||Lower Price Target||$1.04 -> $0.83||High|
|6/1/2016||Royal Bank Of Canada||Lower Price Target||Underperform||$1.00 -> $0.15||N/A|
|4/28/2016||JMP Securities||Reiterated Rating||Hold||N/A|
|4/1/2016||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Sell||N/A|
|1/6/2016||Griffin Securities||Upgrade||Neutral -> Buy||$4.00||N/A|
|11/14/2015||Jefferies Group LLC||Reiterated Rating||Buy||$9.00||N/A|
Earnings History for MannKind Corporation (NASDAQ:MNKD)Earnings History by Quarter for MannKind Corporation (NASDAQ MNKD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2017||Q1 2017||($0.09)||($0.17)||$3.50 million||$3.00 million||View||N/A|
|3/16/2017||Q4 2016||($0.20)||($0.19)||$6.00 million||$12.40 million||View||N/A|
|11/9/2016||Q3 2016||($0.06)||$0.26||$2.00 million||$162.35 million||View||Listen|
Earnings Estimates for MannKind Corporation (NASDAQ:MNKD)
Current Year EPS Consensus Estimate: $-0.87 EPS
Next Year EPS Consensus Estimate: $-0.80 EPS
Dividend History for MannKind Corporation (NASDAQ:MNKD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for MannKind Corporation (NASDAQ:MNKD)
Insider Ownership Percentage: 1.60%Insider Trades by Quarter for MannKind Corporation (NASDAQ:MNKD)
Institutional Ownership Percentage: 17.73%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/3/2017||Matthew J Pfeffer||CEO||Buy||4,540||$0.54||$2,451.60|| |
|1/3/2017||Rosabel Realica Alinaya||SVP||Buy||9,043||$0.54||$4,883.22|| |
|8/26/2016||Michael Castagna||Insider||Buy||17,500||$0.78||$13,650.00|| |
|8/24/2016||Michael Castagna||Insider||Buy||15,000||$0.87||$13,050.00|| |
|8/23/2016||Michael Castagna||Insider||Buy||25,000||$0.94||$23,500.00|| |
|8/15/2016||Matthew J Pfeffer||CEO||Buy||25,000||$0.99||$24,750.00|| |
|8/12/2016||Michael Castagna||Insider||Buy||25,000||$1.00||$25,000.00|| |
|5/17/2016||Michael Castagna||Insider||Buy||50,000||$0.93||$46,500.00|| |
|4/24/2015||Hakan Edstrom||CEO||Sell||73,460||$4.83||$354,811.80|| |
|3/27/2015||Hakan Edstrom||CEO||Sell||73,460||$5.21||$382,726.60|| |
|2/10/2015||Hakan Edstrom||CEO||Sell||73,460||$7.75||$569,315.00|| |
|2/5/2015||David Thomson||VP||Sell||80,000||$7.00||$560,000.00|| |
|1/5/2015||Diane Palumbo||VP||Sell||188,999||$5.95||$1,124,544.05|| |
|11/24/2014||David Thomson||VP||Sell||118,114||$6.14||$725,219.96|| |
|10/3/2014||Juergen Martens||VP||Sell||63,800||$5.48||$349,624.00|| |
|8/27/2014||Juergen Martens||VP||Sell||417||$7.60||$3,169.20|| |
|8/7/2014||David Thomson||VP||Sell||30,000||$8.16||$244,800.00|| |
|7/21/2014||Juergen Martens||VP||Sell||26,458||$9.65||$255,319.70|| |
|7/15/2014||Diane Palumbo||VP||Sell||17,901||$10.01||$179,189.01|| |
|7/1/2014||Matthew J Pfeffer||CFO||Sell||20,000||$10.44||$208,800.00|| |
|6/30/2014||Hakan Edstrom||COO||Buy||1,692||$4.42||$7,478.64|| |
|6/27/2014||Juergen Martens||VP||Sell||25,417||$10.53||$267,641.01|| |
|6/26/2014||David Thomson||VP||Sell||30,000||$10.51||$315,300.00|| |
|6/20/2014||Juergen Martens||VP||Sell||1,458||$10.34||$15,075.72|| |
|6/16/2014||Diane Palumbo||VP||Sell||17,902||$10.59||$189,582.18|| |
|6/5/2014||Juergen Martens||VP||Sell||120,000||$11.00||$1,320,000.00|| |
|6/4/2014||David Thomson||VP||Sell||133,000||$9.95||$1,323,350.00|| |
|6/3/2014||Diane Palumbo||VP||Sell||52,957||$9.50||$503,091.50|| |
|5/23/2014||Juergen Martens||VP||Sell||25,000||$7.65||$191,250.00|| |
|5/19/2014||Juergen Martens||VP||Sell||76,899||$7.50||$576,742.50|| |
|5/15/2014||Diane Palumbo||VP||Sell||18,176||$7.06||$128,322.56|| |
|1/24/2014||Juergen Martens||VP||Sell||50,000||$5.56||$278,000.00|| |
|12/31/2013||Hakan Edstrom||COO||Buy||1,589||$4.53||$7,198.17|| |
|12/20/2013||Juergen Martens||VP||Sell||32,054||$5.00||$160,270.00|| |
|12/11/2013||David Thomson||VP||Sell||150,000||$5.00||$750,000.00|| |
|11/29/2013||Juergen Martens||VP||Sell||48,057||$5.01||$240,765.57|| |
|11/15/2013||Diane Palumbo||VP||Sell||25,000||$5.02||$125,500.00|| |
|8/28/2013||David Thomson||VP||Sell||19,204||$5.78||$110,999.12|| |
|8/26/2013||Juergen Martens||VP||Sell||20,000||$5.52||$110,400.00|| |
|8/1/2013||Matthew J Pfeffer||CFO||Sell||10,000||$8.00||$80,000.00|| |
|7/2/2013||Matthew J Pfeffer||CFO||Sell||10,000||$7.00||$70,000.00|| |
|6/30/2013||Diane Palumbo||VP||Buy||1,610||$1.96||$3,155.60|| |
|6/30/2013||Matthew J Pfeffer||CFO||Buy||7,448||$1.96||$14,598.08|| |
|6/3/2013||Diane Palumbo||VP||Sell||66,849||$7.50||$501,367.50|| |
|5/16/2013||Diane Palumbo||VP||Sell||26,829||$5.25||$140,852.25|| |
|5/15/2013||Matthew J Pfeffer||CFO||Sell||10,000||$5.00||$50,000.00|| |
|12/31/2012||Matthew J Pfeffer||CFO||Buy||1,056||$1.95||$2,059.20|| |
|12/21/2012||Alfred E Mann||Major Shareholder||Buy||40,000,000||$2.59||$103,600,000.00|| |
Headline Trends for MannKind Corporation (NASDAQ:MNKD)
Latest Headlines for MannKind Corporation (NASDAQ:MNKD)
MannKind Corporation (MNKD) Chart for Wednesday, June, 28, 2017